Literature DB >> 24363125

Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems.

Yeon Hong Lee1, Kyung Hee Kim, In Kyung Yoon, Kyung Eun Lee, In Koo Chun, Jeong Yeon Rhie, Hye Sun Gwak.   

Abstract

The objective of this study was to investigate the pharmacokinetic characteristics of levodopa (L-dopa) from nasal powder formulations using highly water-soluble levodopa methyl ester hydrochloride (LDME). In vivo pharmacokinetic studies were carried out with formulated LDME nasal powders. After oral and intravenous administration of L-dopa and carbidopa and intranasal administration LDME to the rat, L-dopa concentrations were determined in plasma and the brain using high-performance liquid chromatography. The absolute bioavailabilities of nasal preparations with and without Carbopol were 82.4 and 66.7 %, respectively, which were much higher than that of oral delivery (16.2 %). The drug-targeting efficiencies [area under the curve (AUC) in brain/AUC in plasma] of L-dopa in the nasal formulations (0.98-1.08) were much higher than that of oral preparation (0.69). These results suggest that LDME nasal powder formulations would be useful delivery systems of L-dopa to the brain.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24363125     DOI: 10.1007/s13318-013-0171-8

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  17 in total

Review 1.  Transport of drugs from the nasal cavity to the central nervous system.

Authors:  L Illum
Journal:  Eur J Pharm Sci       Date:  2000-07       Impact factor: 4.384

2.  Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.

Authors:  H D Kao; A Traboulsi; S Itoh; L Dittert; A Hussain
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

3.  Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.

Authors:  Chukwuemeka S Okereke
Journal:  J Pharm Pharm Sci       Date:  2002 May-Aug       Impact factor: 2.327

Review 4.  The nasal delivery of drugs.

Authors:  M S Quraishi; N S Jones; J D Mason
Journal:  Clin Otolaryngol Allied Sci       Date:  1997-08

5.  Nasal absorption of propranolol from different dosage forms by rats and dogs.

Authors:  A Hussain; S Hirai; R Bawarshi
Journal:  J Pharm Sci       Date:  1980-12       Impact factor: 3.534

Review 6.  Cyclodextrins in drug delivery: an updated review.

Authors:  Rajeswari Challa; Alka Ahuja; Javed Ali; R K Khar
Journal:  AAPS PharmSciTech       Date:  2005-10-14       Impact factor: 3.246

7.  A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.

Authors:  S Grange; N H Holford; T W Guentert
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

8.  Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.

Authors:  Thomas Müller; Christoph Erdmann; Dirk Bremen; Wolfgang E Schmidt; Siegfried Muhlack; Dirk Woitalla; Oliver Goetze
Journal:  Clin Neuropharmacol       Date:  2006 Mar-Apr       Impact factor: 1.592

9.  Design and evaluation of levodopa methyl ester intranasal delivery systems.

Authors:  In Koo Chun; Yeon Hong Lee; Kyung Eun Lee; Hye Sun Gwak
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

10.  The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease.

Authors:  Nicolas Simon; Radka Gantcheva; Bernard Bruguerolle; François Viallet
Journal:  Parkinsonism Relat Disord       Date:  2004-03       Impact factor: 4.891

View more
  5 in total

Review 1.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 2.  Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.

Authors:  Fatma Haddad; Maryam Sawalha; Yahya Khawaja; Anas Najjar; Rafik Karaman
Journal:  Molecules       Date:  2017-12-25       Impact factor: 4.411

Review 3.  Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.

Authors:  Jie Dong; Yanhua Cui; Song Li; Weidong Le
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

4.  Design and Development of Levodopa Loaded Polymeric Nanoparticles for Intranasal Delivery.

Authors:  Mohd Zulhelmy Ahmad; Akmal Hidyat Bin Sabri; Qonita Kurnia Anjani; Juan Domínguez-Robles; Normala Abdul Latip; Khuriah Abdul Hamid
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-18

Review 5.  Prodrug Therapies for Infectious and Neurodegenerative Diseases.

Authors:  Milica Markovic; Suyash Deodhar; Jatin Machhi; Pravin Yeapuri; Maamoon Saleh; Benson J Edagwa; Rodney Lee Mosley; Howard E Gendelman
Journal:  Pharmaceutics       Date:  2022-02-26       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.